艾康片制备工艺药效学筛选研究
|
摘要
目的:从药效学角度筛选艾康片3种提取工艺在抑制肿瘤生长方面效果最佳者,为艾康片进一步工艺提取提供参考。方法:选取BALB/CA-nu裸小鼠,于右前肢腋皮下接种肿瘤细胞悬液建立移植性肺癌模型,建模后将鼠随机分为11组,分别为模型对照组,阳性药物对照组,艾康1号高、中、低,艾康2号高、中、低,艾康3号高、中、低剂量组。分组后当天开始灌胃给药,每日1次,连续21 d,每隔3日测定裸鼠的体质量及肿瘤体积,3周后取肿瘤组织,计算每组平均瘤重、肿瘤生长抑制率、肿瘤体积、相对肿瘤体积、相对肿瘤增殖率。结果:与模型对照组比较,艾康片3个样品各剂量组肿瘤体积及瘤块均明显下降(P<0.01)。艾康3号中剂量组的相对肿瘤增殖体积在给药期间与模型对照组比较有差异(P<0.05)。艾康3号中剂量组的相对肿瘤增殖率为28.72%,低于其它给药组。结论:艾康片对人肺腺癌细胞株(A549)裸鼠的肿瘤增长有一定的抑制作用,艾康片3号中剂量组对肿瘤的抑制作用最佳。
Objective: To investigate the optimal extraction technology of Aikang Tablets in terms of inhibiting tumor growth from the perspective of pharmacodynamics, thus to provide references for further extraction of Aikang Tablets. Methods: design three different doses groups(which is equivalent to 2 times, equimultiple, 1/2 times of clinical dosage). Lung carcinoma xenografts were set up by inoculating A549 cells suspensionin to the right forlimb subcutaneously in the BALB/CA-nu nude mice. When tumor grew to about 100 mm~3, nude mice were randomly divided into the 11 groups: the model group, the positive control group(Compound Cyclophosphamide Tablets), the group of Aikang Tablet 1(high-dose, medium-dose and low-dose), the group of Aikang Tablet 2(high-dose, medium-dose and low-dose), and the group of Aikang Tablet 3(high-dose, medium-dose and low-dose). The medication was once per day for 21 days. The tumor volume and the mice weight were measured every four days. After three weeks, the tumor tissue were collected and weighted, tumor growth inhibition rate, tumor volume, relative tumor growth volume, and relative tumor proliferation rate were calculated at the same time. Results: The gross tumor volume and tumor mass were significantly reduced in the three groups of Aikang Tablets when compared to those in the control group(P<0.01). The relative tumor growth volume in the group of Aikang Tablets 3 of medium-dose was significantly lower than that of the control group(P<0.05). The relative tumor proliferation rate was 28.72% in the group of Aikang Tablets 3 of medium-dose, compared to that in the other medication groups. Conclusion: Aikang Tablets can inhibit tumor growth, medium dose of Aikang Tablets 3 has the best effect.
Objective: To investigate the optimal extraction technology of Aikang Tablets in terms of inhibiting tumor growth from the perspective of pharmacodynamics, thus to provide references for further extraction of Aikang Tablets. Methods: design three different doses groups(which is equivalent to 2 times, equimultiple, 1/2 times of clinical dosage). Lung carcinoma xenografts were set up by inoculating A549 cells suspensionin to the right forlimb subcutaneously in the BALB/CA-nu nude mice. When tumor grew to about 100 mm~3, nude mice were randomly divided into the 11 groups: the model group, the positive control group(Compound Cyclophosphamide Tablets), the group of Aikang Tablet 1(high-dose, medium-dose and low-dose), the group of Aikang Tablet 2(high-dose, medium-dose and low-dose), and the group of Aikang Tablet 3(high-dose, medium-dose and low-dose). The medication was once per day for 21 days. The tumor volume and the mice weight were measured every four days. After three weeks, the tumor tissue were collected and weighted, tumor growth inhibition rate, tumor volume, relative tumor growth volume, and relative tumor proliferation rate were calculated at the same time. Results: The gross tumor volume and tumor mass were significantly reduced in the three groups of Aikang Tablets when compared to those in the control group(P<0.01). The relative tumor growth volume in the group of Aikang Tablets 3 of medium-dose was significantly lower than that of the control group(P<0.05). The relative tumor proliferation rate was 28.72% in the group of Aikang Tablets 3 of medium-dose, compared to that in the other medication groups. Conclusion: Aikang Tablets can inhibit tumor growth, medium dose of Aikang Tablets 3 has the best effect.
引文
[1] Xiao Y,Tian C,Huang T,et al.8-Cetylberberine inhibits growth of lung cancer in vitro and in vivo[J].Life Sciences,2018,1(192):259-269.
[2] Zeng Y,Wang XW,Yin BJ,et al.Role of the stromal cell derived factor-1/CXC chemokine receptor 4 axis in the invasion and metastasis of lung cancer and mechanism[J].J Thorac Dis,2017,9(12):4947-4959.
[3] 马春华,郭志.重组人血管内皮抑制素注射液联合冷冻消融治疗肺腺癌A549移植瘤的实验研究[J].介入放射学杂志,2014,23(3):241-244.
[4] 刘韫宁,齐金蕾,刘江美,等.1990年与2013年中国人群肺癌疾病负担分析[J].中华流行病学杂志,2016,37(6):752-757.
[5] Noone AM,Gronin KA,Altekruse SF,et al.Cancer incidence and survivaltrends by subtype using date from the surveillance epidemiology and end results program,1992-2013[J].Cancer Epidemiol Biomarks Prev,2016,7(2):520-521.
[6] Chen W,Zheng R,Zhang S,et al.Global Cancer statistics,2012[J].Ann Transl Med,2014,2(7):61-65.
[7] Dolgin E.Animal testing altermatives come alive in US[J].Nat Med,2010,16(12):1348.
[8] 胡丽丽,阮永华.移植性肺癌动物模型的建立和研究进展[J].临床与实验病理学杂志,2012,28(8):906-908.
[2] Zeng Y,Wang XW,Yin BJ,et al.Role of the stromal cell derived factor-1/CXC chemokine receptor 4 axis in the invasion and metastasis of lung cancer and mechanism[J].J Thorac Dis,2017,9(12):4947-4959.
[3] 马春华,郭志.重组人血管内皮抑制素注射液联合冷冻消融治疗肺腺癌A549移植瘤的实验研究[J].介入放射学杂志,2014,23(3):241-244.
[4] 刘韫宁,齐金蕾,刘江美,等.1990年与2013年中国人群肺癌疾病负担分析[J].中华流行病学杂志,2016,37(6):752-757.
[5] Noone AM,Gronin KA,Altekruse SF,et al.Cancer incidence and survivaltrends by subtype using date from the surveillance epidemiology and end results program,1992-2013[J].Cancer Epidemiol Biomarks Prev,2016,7(2):520-521.
[6] Chen W,Zheng R,Zhang S,et al.Global Cancer statistics,2012[J].Ann Transl Med,2014,2(7):61-65.
[7] Dolgin E.Animal testing altermatives come alive in US[J].Nat Med,2010,16(12):1348.
[8] 胡丽丽,阮永华.移植性肺癌动物模型的建立和研究进展[J].临床与实验病理学杂志,2012,28(8):906-908.